Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect

详细信息    查看全文

• 作者：Beth Davison Weatherley ; Gad Cotter ; Howard C. Dittrich ; Paul DeLucca ; George A. Mansoor ; Daniel M. Bloomfield ; Piotr Ponikowski ; Christopher M. O'Connor ; Marco Metra ; Barry M. Massie ; PROTECT Steeri
• 关键词：Acute decompensated heart failure ; adenosine A₁ receptor antagonists ; renal function ; rolofylline
• 刊名：Journal of Cardiac Failure
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：16
• 期：1
• 页码：25-35
• 全文大小：217 K

文摘

Background

Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and high mortality. Studies have consistently demonstrated an association between worsening renal function in ADHF and adverse outcomes. Adenosine A₁ receptor antagonists, such as rolofylline, appear in preliminary studies to produce potentially beneficial effects on natriuresis, diuresis, renal blood flow, and glomerular filtration rate. In a previous dose-finding study, rolofylline 30 mg intravenously daily for 3 days was associated with symptom improvement, less worsening of renal function, and trends toward lower 60-day rates of death or readmission for cardiovascular or renal causes.

Methods and Results

This manuscript describes the rationale underlying the design of the phase 3 PROTECT (Placebo-controlled Randomized study of the selective A₁ adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion) trial.

Conclusion

Rolofylline 30 mg or matching placebo was given intravenously as a 4-hour continuous infusion on 3 consecutive days and the hospital course was assessed by measurements dyspnea, clinical status, renal function, and subsequent morbidity and mortality in a large population of patients with ADHF with renal impairment.